- Global Pharma News & Resources

Novastell’s Preminity: a bold new ingredient to reduce PMS & PMDD symptoms

Press Release

August 2022


Novastell’s Preminity: a bold new ingredient to reduce PMS & PMDD symptoms


Novastell, a specialist supplier of phospholipids and other essential ingredients to the health and wellness industry, is proud to announce the launch of Preminity. This innovative ingredient is aimed at women who suffer from the effects of premenstrual syndrome (PMS).


Preminity is a strategic group of membrane-building phospholipids that, when used in a supplement, can assist in managing chronic stress. Brain and nerve cells need these essential nutrients in high concentrations and studies show that the combination can be used to minimise stress response. Preminity’s formula delivers results beyond a single phospholipid supplementation been proven to reduce PMS symptoms and stress indicators.


Globally, many pre-menopausal women experience a variety of symptoms in the two weeks before menses. These include emotional changes, irritability, bloating, tiredness, sleep disturbances and elevated cortisol levels.


“In some instances, these symptoms can have a profound effect a woman’s quality of life. In severe cases, it can lead to premenstrual dysphoric disorder (PMDD) - a more serious manifestation of PMS,” explained Carla Felgueiras, global ingredient portfolio manager at Novastell.


PMDD causes acute irritability, depression, and anxiety in the weeks before a woman’s period starts. While symptoms usually go away two to three days after menstruation, some women may need medicine or other treatment, including supplements to help control their symptoms.


One of the ways to control PMS and PMDD symptoms is by controlling chronic stress in the human body. While stress is a normal physiological function, negative stress can be the consequence of an overstimulation of a hormonal pathway, called the hypothalamic-pituitary-adrenal (HPA) axis.


Activation of the HPA axis is associated with increased levels of cortisol and the corticotropin-releasing hormone (CRH) intended to control stress response in the body.


“Preminity is a patented ingredient that combines phosphatidylserine and phosphatidic acid. In a recent randomised, placebo-controlled, double-blind human clinical trial, a combination of phosphatidylserine and phosphatidic acid were shown to effectively reduce the symptoms of PMS,” Felgueiras noted. “During the trial, the total reduction in PMS symptom severity was significantly larger for the treatment group than the placebo group and the assessed DRSP total score showed a highly significant improvement.


Understanding the complexity of PMS and how it affects women is one step forward towards minimising the discomfort experienced by so many. “Making use of this highly innovative compound will enable brand owners to develop products that can target negative stress and other factors synergistically - ensuring that that time of the month does not have to be a stressful and difficult period for women,” Felgueiras concluded.


For more information on Preminity and how you can use it during formulation, contact the Novastell team now at


Editor Details

Last Updated: 04-Aug-2022